Pharmaceuticals
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP34...
Bio Investments Group (BIG) and International Vaccine Institute (IVI) Forge Partnership to Accelerate Vaccine Self-Reliance in Africa and the Middle East
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery,...
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics,...
DKSH and Bayer Launch Strategic Partnership Across Multiple Markets in Southeast Asia
DKSH has signed a strategic business partnership with life science company Bayer, to provide comprehensive services for a portion of the Bayer Pharmaceuticals business in Singapore, Malaysia, Thailand and the Philippines. SINGAPORE, July 10, 2025 /PRNewswire/ -- DKSH Business Unit Healthcare, ...
Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
SHANGHAI, July 9, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 ...
LBB Specialties Expands Distribution Partnership with Clariant to Support Puerto Rico's Life Sciences Market
NORWALK, Conn., July 9, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce the expansion of its distribution partnership with Clariant, a global leader in the development and manufacturing of specialty c...
NYSE Content advisory: Pre-Market update + Trump announces 50% levy on copper imports
NEW YORK, July 9, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content advisory: Pre-Market update + Trump announces 50% le...
GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability
PISCATAWAY, N.J., July 9, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment plat...
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel
SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced thatits self-developed an...
Gozellix Receives Permanent HCPCS Code
MELBOURNE, Australia, July 9, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that its next-generation PSMA[1] PET[2] imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Hea...
Watson-Marlow Fluid Technology Solutions focuses on BioClamp's sustainability benefits and new WMArchitect Interchangeable Parts service at INTERPHEX Tokyo 2025
TOKYO, July 9, 2025 /PRNewswire/ -- Visitors to the Watson-Marlow Fluid Technology Solutions booth W15-2 at INTERPHEX Tokyo 2025 (July 9-11 at Tokyo Big Sight, Japan) can learn more about the new WMArchitect Interchangeable Parts service as well as how recently advanced manufacturing of BioClamp ...
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of...
GLOBAL NUTRACEUTICALS CAMPAIGN TO RAISE FUNDS FOR RESCUE SHELTER FOR CHILD SEXUAL ABUSE SURVIVORS
#HopeNeedsAHome Cypress Minerals and Cepham Inc lead Fundraising Efforts Because Hope Needs A Home - Deadline Looms As Mothers, Aged 11-17, Hope For Sanctuary they can call Home $140,000 USD needed by August 15 to Secure Home for young Mothers MADERA, Calif., July 8, 2025 /PRNewswire/ -- Tw...
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently provided updates to investors on the st...
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] * STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially availa...
SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V
SINGAPORE, July 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical Products Administration (NMPA) has cleared the Investigation...
WuXi AppTec Receives MSCI ESG AAA Leader Rating
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its lates...
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor
ESG | HitGen Releases Its Inaugural Sustainability Report
CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG")...
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27